Taiwo Opeyemi Aremu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Taiwo Opeyemi Aremu has a total of 106 co-authors. Here are the top co-authors by number of shared publications:
- Oluwatosin Esther Oluwole
Division of Epidemiology & Community Health, School of Public Health, University of Minnesota, 300 West Bank Office Building, 1300 S. 2nd Street, Minneapolis, MN 55454, USA
6 shared publications - Kehinde Oluwatosin Adeyinka
11 Radiation Oncology, University College Hospital (UCH), Ibadan, NGA
5 shared publications - Olihe Okoro
Department of Pharmacy Practice and Pharmaceutical Sciences, College of Pharmacy, University of Minnesota Duluth, 235 Life Science, Duluth, MN 55812, USA
5 shared publications - Jon C. Schommer
Department of Pharmaceutical Care & Health Systems (PCHS), College of Pharmacy, University of Minnesota, 308 Harvard Street SE, Minneapolis, MN 55455, USA
4 shared publications - Caroline Gaither
Department of Pharmaceutical Care & Health Systems (PCHS), College of Pharmacy, University of Minnesota, 308 Harvard Street SE, Minneapolis, MN 55455, USA
3 shared publications - Drissa Makan Toure
Division of Epidemiology & Community Health, School of Public Health, University of Minnesota, Minneapolis, United States, USA
3 shared publications
Latest Publications
- Open Access
- 9 October 2026
- Published by MDPI AG in Medical Sciences
- Vol. 14 (6) , 651
Examining Regulatory Classifications and Social Determinants of Health in Telehealth-Mediated ADHD Prescription Fulfillment Barriers
Background: Telehealth has expanded remote access to ADHD care, yet a prescription issued remotely must still be filled at a pharmacy—and whether telehealth resolves these downstream fulfillment barriers remains unclear. Federal regulatory distinctions between Schedule II controlled stimulants and non-controlled ADHD pharmacotherapies create structurally divergent procurement experiences, particularly under ongoing nationwide stimulant shortages. This study examined whether prescription fulfillment difficulty differs by medication regulatory classification among adults using telehealth for ADHD care, and identified social determinants of health (SDOH) associated with access difficulty. Methods: Data were drawn from Round 2 of the NCHS Rapid Surveys System (RSS-2; October–November 2023). The analytic sample comprised 141 adults with a current ADHD diagnosis who reported pharmacotherapy use and telehealth utilization for ADHD care, classified as controlled-exposed (n = 95) or non-controlled-exposed (n = 46) by medication regulatory class. Chi-square tests, multivariable logistic regression, and five machine learning algorithms were applied across 19 SDOH variables. Results: Prescription access difficulty was substantially more prevalent among controlled-exposed than non-controlled-exposed participants (75.8% vs. 45.7%, p < 0.001). Multivariable logistic regression identified controlled medication exposure (coefficient = 2.155, p < 0.001), difficulty paying medical bills (coefficient = 1.409, p = 0.034), and income (coefficient = 0.145, p = 0.042) as significant correlates. Random Forest permutation importance ranked controlled medication exposure and having a usual place for care as the two strongest predictors, although these exploratory rankings warrant caution given the small held-out test set (n = 28). Notably, all 13 participants reporting non-prescribed online medication purchases also reported access difficulty through formal channels, a pattern consistent with displacement toward unregulated supply chains. Conclusions: Prescription fulfillment barriers were strongly stratified by medication regulatory classification, with financial strain further compounding access difficulty. As federal telemedicine flexibilities approach their 31 December 2026, expiration, regulatory deliberations should weigh downstream fulfillment constraints—including the Schedule II refill prohibition under shortage conditions—alongside upstream telehealth access.
- 9 October 2026
- Published by MDPI AG in Medical Sciences
- Vol. 14 (6) , 651
Open AccessExamining Regulatory Classifications and Social Determinants of Health in Telehealth-Mediated ADHD Prescription Fulfillment Barriers
Background: Telehealth has expanded remote access to ADHD care, yet a prescription issued remotely must still be filled at a pharmacy—and whether telehealth resolves these downstream fulfillment barriers remains unclear. Federal regulatory distinctions between Schedule II controlled stimulants and non-controlled ADHD pharmacotherapies create structurally divergent procurement experiences, particularly under ongoing nationwide stimulant shortages. This study examined whether prescription fulfillment difficulty differs by medication regulatory classification among adults using telehealth for ADHD care, and identified social determinants of health (SDOH) associated with access difficulty. Methods: Data were drawn from Round 2 of the NCHS Rapid Surveys System (RSS-2; October–November 2023). The analytic sample comprised 141 adults with a current ADHD diagnosis who reported pharmacotherapy use and telehealth utilization for ADHD care, classified as controlled-exposed (n = 95) or non-controlled-exposed (n = 46) by medication regulatory class. Chi-square tests, multivariable logistic regression, and five machine learning algorithms were applied across 19 SDOH variables. Results: Prescription access difficulty was substantially more prevalent among controlled-exposed than non-controlled-exposed participants (75.8% vs. 45.7%, p < 0.001). Multivariable logistic regression identified controlled medication exposure (coefficient = 2.155, p < 0.001), difficulty paying medical bills (coefficient = 1.409, p = 0.034), and income (coefficient = 0.145, p = 0.042) as significant correlates. Random Forest permutation importance ranked controlled medication exposure and having a usual place for care as the two strongest predictors, although these exploratory rankings warrant caution given the small held-out test set (n = 28). Notably, all 13 participants reporting non-prescribed online medication purchases also reported access difficulty through formal channels, a pattern consistent with displacement toward unregulated supply chains. Conclusions: Prescription fulfillment barriers were strongly stratified by medication regulatory classification, with financial strain further compounding access difficulty. As federal telemedicine flexibilities approach their 31 December 2026, expiration, regulatory deliberations should weigh downstream fulfillment constraints—including the Schedule II refill prohibition under shortage conditions—alongside upstream telehealth access.
- Open Access
- 15 September 2026
- Published by MDPI AG in Preprints.org
Examining Regulatory Classifications and Social Determinants of Health in Telehealth-Mediated ADHD Prescription Fulfillment Barriers
Background: Telehealth has expanded remote access to ADHD care, yet a prescription issued remotely must still be filled at a pharmacy—and whether telehealth resolves these downstream fulfillment barriers remains unclear. Federal regulatory distinctions between Schedule II controlled stimulants and non-controlled ADHD pharmacotherapies create structurally divergent procurement experiences, particularly under ongoing nationwide stimulant shortages. This study examined whether prescription fulfillment difficulty differs by medication regulatory classification among adults using telehealth for ADHD care, and identified social determinants of health (SDOH) associated with access difficulty. Methods: Data were drawn from Round 2 of the NCHS Rapid Surveys System (RSS-2; October–November 2023). The analytic sample comprised 141 adults with a current ADHD diagnosis who reported pharmacotherapy use and telehealth utilization for ADHD care, classified as controlled-exposed (n = 95) or non-controlled-exposed (n = 46) by medication regulatory class. Chi-square tests, multivariable logistic regression, and five machine learning algorithms were applied across 19 SDOH variables. Results: Prescription access difficulty was substantially more prevalent among controlled-exposed than non-controlled-exposed participants (75.8% vs. 45.7%, p < 0.001). Multivariable logistic regression identified controlled medication exposure (coefficient = 2.155, p < 0.001), difficulty paying medical bills (coefficient = 1.409, p = 0.034), and income (coefficient = 0.145, p = 0.042) as significant correlates. Random forest permutation importance ranked controlled medication exposure and having a usual place for care as the two strongest predictors. Notably, all 13 participants reporting non-prescribed online medication purchases also reported access difficulty through formal channels, a pattern consistent with displacement toward unregulated supply chains. Conclusions: Prescription fulfillment barriers were strongly stratified by medication regulatory classification, with financial strain further compounding access difficulty. As federal telemedicine flexibilities approach their December 31, 2026, expiration, regulatory deliberations should weigh downstream fulfillment constraints, including the Schedule II refill prohibition under shortage conditions, alongside upstream telehealth access.
- 15 September 2026
- Published by MDPI AG in Preprints.org
Open AccessExamining Regulatory Classifications and Social Determinants of Health in Telehealth-Mediated ADHD Prescription Fulfillment Barriers
Background: Telehealth has expanded remote access to ADHD care, yet a prescription issued remotely must still be filled at a pharmacy—and whether telehealth resolves these downstream fulfillment barriers remains unclear. Federal regulatory distinctions between Schedule II controlled stimulants and non-controlled ADHD pharmacotherapies create structurally divergent procurement experiences, particularly under ongoing nationwide stimulant shortages. This study examined whether prescription fulfillment difficulty differs by medication regulatory classification among adults using telehealth for ADHD care, and identified social determinants of health (SDOH) associated with access difficulty. Methods: Data were drawn from Round 2 of the NCHS Rapid Surveys System (RSS-2; October–November 2023). The analytic sample comprised 141 adults with a current ADHD diagnosis who reported pharmacotherapy use and telehealth utilization for ADHD care, classified as controlled-exposed (n = 95) or non-controlled-exposed (n = 46) by medication regulatory class. Chi-square tests, multivariable logistic regression, and five machine learning algorithms were applied across 19 SDOH variables. Results: Prescription access difficulty was substantially more prevalent among controlled-exposed than non-controlled-exposed participants (75.8% vs. 45.7%, p < 0.001). Multivariable logistic regression identified controlled medication exposure (coefficient = 2.155, p < 0.001), difficulty paying medical bills (coefficient = 1.409, p = 0.034), and income (coefficient = 0.145, p = 0.042) as significant correlates. Random forest permutation importance ranked controlled medication exposure and having a usual place for care as the two strongest predictors. Notably, all 13 participants reporting non-prescribed online medication purchases also reported access difficulty through formal channels, a pattern consistent with displacement toward unregulated supply chains. Conclusions: Prescription fulfillment barriers were strongly stratified by medication regulatory classification, with financial strain further compounding access difficulty. As federal telemedicine flexibilities approach their December 31, 2026, expiration, regulatory deliberations should weigh downstream fulfillment constraints, including the Schedule II refill prohibition under shortage conditions, alongside upstream telehealth access.
- Open Access
Willingness to Accept a Locally Manufactured COVID-19 Vaccine in Lagos, Nigeria: A Cross-Sectional Survey and Demographic Predictors
Background: Local vaccine manufacturing is being pursued across Africa to improve pandemic preparedness and reduce reliance on imports. In Nigeria, where COVID-19 vaccines were largely imported, willingness to accept locally produced vaccines is important for sustainable domestic production. The objective of this study was to estimate willingness to accept a locally manufactured COVID-19 vaccine among adults in Lagos, Nigeria, and to identify demographic predictors. Methods: We conducted a cross-sectional survey of adults in Lagos State from 7 September to 16 September 2024, using a questionnaire administered in four open-air markets. The primary outcome was willingness to accept a COVID-19 vaccine manufactured in Nigeria (yes/no). We summarized respondent characteristics, tested bivariate associations using chi-square tests, and estimated adjusted odds ratios (AORs) using multivariable logistic regression. Model calibration and discrimination were assessed using Hosmer–Lemeshow testing and the area under the ROC curve (AUC). Results: Of 388 consenting respondents, 335 provided complete data (86.3%). Respondents were predominantly female (60.6%); the largest age groups were 25–34 (30.2%) and 35–44 (28.4%) years. Overall, 75.8% reported willingness to accept a Nigerian-made COVID-19 vaccine. Willingness differed by age group (p = 0.0028; trend p = 0.0002) and religion (p = 0.0403). In adjusted models, respondents aged 45–54 years (aOR 6.54; 95% CI: 1.73–24.79) and 55–64 years (aOR 4.97; 95% CI: 1.05–23.55) had higher odds of acceptance than those aged 18–24 years. Christian affiliation was associated with lower odds than Muslim affiliation (aOR 0.41; 95% CI: 0.20–0.83). Discrimination was acceptable (AUC 0.75; 95% CI: 0.69–0.80). Conclusions: Most respondents were willing to accept a Nigerian-made COVID-19 vaccine, suggesting demand-side readiness. Confidence-building strategies tailored to younger adults and implemented with faith-based and community institutions may support uptake of locally produced vaccines.
Open AccessWillingness to Accept a Locally Manufactured COVID-19 Vaccine in Lagos, Nigeria: A Cross-Sectional Survey and Demographic Predictors
Background: Local vaccine manufacturing is being pursued across Africa to improve pandemic preparedness and reduce reliance on imports. In Nigeria, where COVID-19 vaccines were largely imported, willingness to accept locally produced vaccines is important for sustainable domestic production. The objective of this study was to estimate willingness to accept a locally manufactured COVID-19 vaccine among adults in Lagos, Nigeria, and to identify demographic predictors. Methods: We conducted a cross-sectional survey of adults in Lagos State from 7 September to 16 September 2024, using a questionnaire administered in four open-air markets. The primary outcome was willingness to accept a COVID-19 vaccine manufactured in Nigeria (yes/no). We summarized respondent characteristics, tested bivariate associations using chi-square tests, and estimated adjusted odds ratios (AORs) using multivariable logistic regression. Model calibration and discrimination were assessed using Hosmer–Lemeshow testing and the area under the ROC curve (AUC). Results: Of 388 consenting respondents, 335 provided complete data (86.3%). Respondents were predominantly female (60.6%); the largest age groups were 25–34 (30.2%) and 35–44 (28.4%) years. Overall, 75.8% reported willingness to accept a Nigerian-made COVID-19 vaccine. Willingness differed by age group (p = 0.0028; trend p = 0.0002) and religion (p = 0.0403). In adjusted models, respondents aged 45–54 years (aOR 6.54; 95% CI: 1.73–24.79) and 55–64 years (aOR 4.97; 95% CI: 1.05–23.55) had higher odds of acceptance than those aged 18–24 years. Christian affiliation was associated with lower odds than Muslim affiliation (aOR 0.41; 95% CI: 0.20–0.83). Discrimination was acceptable (AUC 0.75; 95% CI: 0.69–0.80). Conclusions: Most respondents were willing to accept a Nigerian-made COVID-19 vaccine, suggesting demand-side readiness. Confidence-building strategies tailored to younger adults and implemented with faith-based and community institutions may support uptake of locally produced vaccines.
- Open Access
Seasonal Influenza Vaccination Uptake, Illness and Economic Burden, and Vaccine Information Exposure Among Young Adults in the San Francisco Bay Area
Background: Seasonal influenza prevention in young adults is influenced by access, trust, and vaccine information exposure, but local evidence linking vaccination uptake with illness and economic burden is limited. Methods: We conducted a non-probability, cross-sectional electronic survey of adults aged 18–49 years who lived, worked, or studied in the San Francisco Bay Area during the 2025 to 2026 influenza season. Measures included vaccination uptake, influenza-like illness, recovery, functional and economic burden, vaccination sites, and vaccine information exposure. Multivariable logistic regression examined factors associated with vaccination uptake; Kaplan–Meier and Cox models examined time to recovery. Results: Of 554 responses, 463 were included. Vaccination uptake was 86.2% (n = 399; 95% confidence interval [CI], 82.7–89.2%), likely reflecting a health-engaged convenience sample. Influenza-like illness was reported by 38.4%; median recovery time was 5 days, median missed work or school was 2 days, and median direct out-of-pocket cost was US$20. Prior season vaccination (adjusted odds ratio [aOR], 2.24; 95% CI, 1.15–4.34) and greater trust in Centers for Disease Control and Prevention (CDC) or public health agencies (aOR, 1.46; 95% CI, 1.05–2.02) were associated with vaccination. Pharmacies were the second most common vaccination site and preferred future site. Conclusions: Influenza prevention for young adults may benefit from pharmacy-inclusive, multichannel access paired with trusted communication. Findings should be interpreted in light of non-probability recruitment and likely overrepresentation of health-engaged respondents.
Open AccessSeasonal Influenza Vaccination Uptake, Illness and Economic Burden, and Vaccine Information Exposure Among Young Adults in the San Francisco Bay Area
Background: Seasonal influenza prevention in young adults is influenced by access, trust, and vaccine information exposure, but local evidence linking vaccination uptake with illness and economic burden is limited. Methods: We conducted a non-probability, cross-sectional electronic survey of adults aged 18–49 years who lived, worked, or studied in the San Francisco Bay Area during the 2025 to 2026 influenza season. Measures included vaccination uptake, influenza-like illness, recovery, functional and economic burden, vaccination sites, and vaccine information exposure. Multivariable logistic regression examined factors associated with vaccination uptake; Kaplan–Meier and Cox models examined time to recovery. Results: Of 554 responses, 463 were included. Vaccination uptake was 86.2% (n = 399; 95% confidence interval [CI], 82.7–89.2%), likely reflecting a health-engaged convenience sample. Influenza-like illness was reported by 38.4%; median recovery time was 5 days, median missed work or school was 2 days, and median direct out-of-pocket cost was US$20. Prior season vaccination (adjusted odds ratio [aOR], 2.24; 95% CI, 1.15–4.34) and greater trust in Centers for Disease Control and Prevention (CDC) or public health agencies (aOR, 1.46; 95% CI, 1.05–2.02) were associated with vaccination. Pharmacies were the second most common vaccination site and preferred future site. Conclusions: Influenza prevention for young adults may benefit from pharmacy-inclusive, multichannel access paired with trusted communication. Findings should be interpreted in light of non-probability recruitment and likely overrepresentation of health-engaged respondents.
- Open Access
- 19 May 2026
- Published by MDPI AG in Preprints.org
Seasonal Influenza Vaccination Uptake, Illness and Economic Burden, and Vaccine Information Exposure among Adults Aged 18 to 49 Years in the San Francisco Bay Area: A Cross-Sectional Survey
Background: Seasonal influenza prevention in young adults is influenced by access, trust, and vaccine information exposure, but local evidence linking vaccination uptake with illness and economic burden is limited. Methods: We conducted a cross-sectional electronic survey of adults aged 18-49 years who lived, worked, or studied in the San Francisco Bay Area during the 2025 to 2026 influenza season. Measures included vaccination uptake, influenza-like illness, recovery, functional and economic burden, vaccination sites, and vaccine information exposure. Multivariable logistic regression examined factors associated with vaccination uptake; Kaplan-Meier and Cox models examined time to recovery. Results: Of 554 responses, 463 were included. Vaccination uptake was 86.2% (n=399; 95% confidence interval [CI], 82.7%-89.2%), and 38.4% reported influenza-like illness. Among those with illness, median recovery time was 5 days, median missed work or school was 2 days, and median direct out-of-pocket cost was US$20. Prior season vaccination (adjusted odds ratio [aOR], 2.24; 95% CI, 1.15-4.34) and greater trust in Centers for Disease Control and Prevention or public health agencies (aOR, 1.46; 95% CI, 1.05-2.02) were associated with vaccination. Pharmacies were the second most common vaccination site and preferred future site. Conclusion: Influenza prevention for young adults may benefit from pharmacy-inclusive, multichannel access paired with trusted communication.
- 19 May 2026
- Published by MDPI AG in Preprints.org
Open AccessSeasonal Influenza Vaccination Uptake, Illness and Economic Burden, and Vaccine Information Exposure among Adults Aged 18 to 49 Years in the San Francisco Bay Area: A Cross-Sectional Survey
Background: Seasonal influenza prevention in young adults is influenced by access, trust, and vaccine information exposure, but local evidence linking vaccination uptake with illness and economic burden is limited. Methods: We conducted a cross-sectional electronic survey of adults aged 18-49 years who lived, worked, or studied in the San Francisco Bay Area during the 2025 to 2026 influenza season. Measures included vaccination uptake, influenza-like illness, recovery, functional and economic burden, vaccination sites, and vaccine information exposure. Multivariable logistic regression examined factors associated with vaccination uptake; Kaplan-Meier and Cox models examined time to recovery. Results: Of 554 responses, 463 were included. Vaccination uptake was 86.2% (n=399; 95% confidence interval [CI], 82.7%-89.2%), and 38.4% reported influenza-like illness. Among those with illness, median recovery time was 5 days, median missed work or school was 2 days, and median direct out-of-pocket cost was US$20. Prior season vaccination (adjusted odds ratio [aOR], 2.24; 95% CI, 1.15-4.34) and greater trust in Centers for Disease Control and Prevention or public health agencies (aOR, 1.46; 95% CI, 1.05-2.02) were associated with vaccination. Pharmacies were the second most common vaccination site and preferred future site. Conclusion: Influenza prevention for young adults may benefit from pharmacy-inclusive, multichannel access paired with trusted communication.
- Open Access
- 24 April 2026
- Published by MDPI AG in Preprints.org
Willingness to Accept a Locally Manufactured COVID-19 Vaccine in Lagos, Nigeria: A Cross-Sectional Survey and Demographic Predictors
Background: Local vaccine manufacturing is being pursued across Africa to improve pandemic preparedness and reduce reliance on imports. In Nigeria, where COVID-19 vaccines were largely imported, willingness to accept locally produced vaccines is important for sustainable domestic production. The objective of this study was to estimate willing-ness to accept a locally manufactured COVID-19 vaccine among adults in Lagos, Nigeria, and to identify demographic predictors. Methods: We conducted a cross-sectional survey of adults in Lagos State using a questionnaire administered in four open-air markets. The primary outcome was willingness to accept a COVID-19 vaccine manufactured in Nigeria (yes/no). We summarized respondent characteristics, tested bivariate associations with chi-square, and estimated adjusted odds ratios (AORs) using multivariable logistic regression. Model calibration and discrimination were assessed using Hosmer-Lemeshow testing and the area under the ROC curve (AUC). Results: Of 388 consenting respondents, 335 provided complete data (86.3%). 75.8% reported willingness to accept a Nigerian-made COVID-19 vaccine. Willingness differed by age group (p=0.0028; trend p=0.0002) and religion (p=0.0403). In adjusted models, respondents aged 45-54 years (AOR 6.54; 95% CI 1.73-24.79) and 55-64 years (AOR 4.97; 95% CI 1.05-23.55) had higher odds of acceptance than those aged 18-24 years. Christian affiliation was associated with lower odds than Muslim affiliation (AOR 0.41; 95% CI 0.20-0.83). Discrimination was acceptable (AUC 0.75; 95% CI 0.69-0.80). Conclusions: Most respondents were willing to accept a Nigerian-made COVID-19 vaccine, suggesting demand-side readiness. Confidence-building strategies tailored to younger adults and implemented with faith-based and community institutions may support uptake of locally produced vaccines.
- 24 April 2026
- Published by MDPI AG in Preprints.org
Open AccessWillingness to Accept a Locally Manufactured COVID-19 Vaccine in Lagos, Nigeria: A Cross-Sectional Survey and Demographic Predictors
Background: Local vaccine manufacturing is being pursued across Africa to improve pandemic preparedness and reduce reliance on imports. In Nigeria, where COVID-19 vaccines were largely imported, willingness to accept locally produced vaccines is important for sustainable domestic production. The objective of this study was to estimate willing-ness to accept a locally manufactured COVID-19 vaccine among adults in Lagos, Nigeria, and to identify demographic predictors. Methods: We conducted a cross-sectional survey of adults in Lagos State using a questionnaire administered in four open-air markets. The primary outcome was willingness to accept a COVID-19 vaccine manufactured in Nigeria (yes/no). We summarized respondent characteristics, tested bivariate associations with chi-square, and estimated adjusted odds ratios (AORs) using multivariable logistic regression. Model calibration and discrimination were assessed using Hosmer-Lemeshow testing and the area under the ROC curve (AUC). Results: Of 388 consenting respondents, 335 provided complete data (86.3%). 75.8% reported willingness to accept a Nigerian-made COVID-19 vaccine. Willingness differed by age group (p=0.0028; trend p=0.0002) and religion (p=0.0403). In adjusted models, respondents aged 45-54 years (AOR 6.54; 95% CI 1.73-24.79) and 55-64 years (AOR 4.97; 95% CI 1.05-23.55) had higher odds of acceptance than those aged 18-24 years. Christian affiliation was associated with lower odds than Muslim affiliation (AOR 0.41; 95% CI 0.20-0.83). Discrimination was acceptable (AUC 0.75; 95% CI 0.69-0.80). Conclusions: Most respondents were willing to accept a Nigerian-made COVID-19 vaccine, suggesting demand-side readiness. Confidence-building strategies tailored to younger adults and implemented with faith-based and community institutions may support uptake of locally produced vaccines.
- Top Cited PapersOpen Access
Global Pharmaceutical Regulation: Comparative Frameworks and Operations
Pharmaceutical regulation plays a central role in protecting public health by governing clinical trials, market authorization, and post-marketing safety monitoring throughout the medicine life cycle. While substantial literature describes established systems, particularly the United States Food and Drug Administration (FDA), Japan’s Pharmaceuticals and Medical Devices Agency (PMDA), and the European medicines regulatory network coordinated by the European Medicines Agency (EMA) together with national competent authorities, comparative analyses that integrate both mature authorities, emerging regulators and transnational harmonization networks remain limited. This narrative review draws on primary regulator/network documentation and targeted peer-reviewed literature to compare core regulatory functions across jurisdictions, including approval pathways and evidentiary expectations, inspection and good manufacturing practice (GMP) oversight, transparency practices, and pharmacovigilance and risk-management approaches. Across regions, we observe increasing convergence in scientific expectations through initiatives such as the International Council for Harmonisation (ICH) and reliance and work-sharing models, alongside persistent differences in legal mandates, resourcing, timelines, and data requirements. These differences are most consequential for complex products (e.g., advanced therapies) and in crisis settings, where emergency or conditional authorizations amplify the need for strong lifecycle monitoring, real-world evidence governance, and cross-border communication. We conclude by outlining opportunities to strengthen regulatory resilience and equity through fit-for-purpose harmonization, investment in enabling infrastructure, and future work on interoperable data systems, signal detection, and coordinated post-marketing evaluation.
Top Cited PapersOpen AccessGlobal Pharmaceutical Regulation: Comparative Frameworks and Operations
Pharmaceutical regulation plays a central role in protecting public health by governing clinical trials, market authorization, and post-marketing safety monitoring throughout the medicine life cycle. While substantial literature describes established systems, particularly the United States Food and Drug Administration (FDA), Japan’s Pharmaceuticals and Medical Devices Agency (PMDA), and the European medicines regulatory network coordinated by the European Medicines Agency (EMA) together with national competent authorities, comparative analyses that integrate both mature authorities, emerging regulators and transnational harmonization networks remain limited. This narrative review draws on primary regulator/network documentation and targeted peer-reviewed literature to compare core regulatory functions across jurisdictions, including approval pathways and evidentiary expectations, inspection and good manufacturing practice (GMP) oversight, transparency practices, and pharmacovigilance and risk-management approaches. Across regions, we observe increasing convergence in scientific expectations through initiatives such as the International Council for Harmonisation (ICH) and reliance and work-sharing models, alongside persistent differences in legal mandates, resourcing, timelines, and data requirements. These differences are most consequential for complex products (e.g., advanced therapies) and in crisis settings, where emergency or conditional authorizations amplify the need for strong lifecycle monitoring, real-world evidence governance, and cross-border communication. We conclude by outlining opportunities to strengthen regulatory resilience and equity through fit-for-purpose harmonization, investment in enabling infrastructure, and future work on interoperable data systems, signal detection, and coordinated post-marketing evaluation.
- Open Access
- 11 March 2026
- Published by MDPI AG in Preprints.org
Building COVID-19 Vaccine Manufacturing Capacity in Nigeria: A Qualitative Needs Assessment of Barriers and Resource Requirements
Background: During the COVID-19 pandemic, Nigeria relied largely on imported vaccines, underscoring vulnerabilities in supply chains and the absence of domestic vaccine manufacturing. Understanding supply-related barriers and the resources required for local vaccine production is critical for future pandemic preparedness and population health outcome. The objective of the study was to identify stakeholder-perceived barriers to COVID‑19 vaccine manufacturing in Nigeria and to describe the resources and enabling conditions required for local production. Methods: We conducted a qualitative needs assessment using semi-structured interviews with senior personnel from Nigerian pharmaceutical manufacturing firms and regulatory agencies. Participants were recruited purposively and consecutively. Interviews (30-60 minutes) were conducted via Zoom, audio-recorded with consent, transcribed, and analyzed using inductive thematic analysis following established six-phase procedures. Reporting adheres to the Consolidated Criteria for Reporting Qualitative Research (COREQ). Results: Six participants (two regulators and four pharmaceutical executives) identified three interrelated barrier to domestic COVID-19 vaccine production: (1) technical and knowledge gaps (loss of hands-on expertise, absence of operational vaccine manufacturing facilities, limited technology transfer), (2) financial and infrastructure barriers (high cost of capital, serial taxation, unreliable electricity and logistics constraints), and (3) systemic and institutional barriers (inconsistent political commitment, policy discontinuity, regulatory capacity gaps, and concerns about public confidence). To enable local production, participants emphasized coordinated investment in workforce development, technology-transfer partnerships, modern utilities and cold chain systems, access to specialized equipment and high-quality inputs, and predictable policy, financing, and regulatory environments. Conclusions: Participants perceived Nigeria’s current capacity as insufficient for COVID-19 vaccine manufacturing but identified actionable levers, particularly human capital development, infra-structure strengthening, and regulatory and financing reforms, to enable sustainable local production. These findings provide a practical roadmap for policymakers, regulators, and industry leaders seeking to strengthen Nigeria’s biomanufacturing and long-term pan-demic preparedness.
- 11 March 2026
- Published by MDPI AG in Preprints.org
Open AccessBuilding COVID-19 Vaccine Manufacturing Capacity in Nigeria: A Qualitative Needs Assessment of Barriers and Resource Requirements
Background: During the COVID-19 pandemic, Nigeria relied largely on imported vaccines, underscoring vulnerabilities in supply chains and the absence of domestic vaccine manufacturing. Understanding supply-related barriers and the resources required for local vaccine production is critical for future pandemic preparedness and population health outcome. The objective of the study was to identify stakeholder-perceived barriers to COVID‑19 vaccine manufacturing in Nigeria and to describe the resources and enabling conditions required for local production. Methods: We conducted a qualitative needs assessment using semi-structured interviews with senior personnel from Nigerian pharmaceutical manufacturing firms and regulatory agencies. Participants were recruited purposively and consecutively. Interviews (30-60 minutes) were conducted via Zoom, audio-recorded with consent, transcribed, and analyzed using inductive thematic analysis following established six-phase procedures. Reporting adheres to the Consolidated Criteria for Reporting Qualitative Research (COREQ). Results: Six participants (two regulators and four pharmaceutical executives) identified three interrelated barrier to domestic COVID-19 vaccine production: (1) technical and knowledge gaps (loss of hands-on expertise, absence of operational vaccine manufacturing facilities, limited technology transfer), (2) financial and infrastructure barriers (high cost of capital, serial taxation, unreliable electricity and logistics constraints), and (3) systemic and institutional barriers (inconsistent political commitment, policy discontinuity, regulatory capacity gaps, and concerns about public confidence). To enable local production, participants emphasized coordinated investment in workforce development, technology-transfer partnerships, modern utilities and cold chain systems, access to specialized equipment and high-quality inputs, and predictable policy, financing, and regulatory environments. Conclusions: Participants perceived Nigeria’s current capacity as insufficient for COVID-19 vaccine manufacturing but identified actionable levers, particularly human capital development, infra-structure strengthening, and regulatory and financing reforms, to enable sustainable local production. These findings provide a practical roadmap for policymakers, regulators, and industry leaders seeking to strengthen Nigeria’s biomanufacturing and long-term pan-demic preparedness.
- Open Access
- 18 February 2026
- Published by Springer Nature in Cureus
- Vol. 18 (2)
Patients’ Perspectives on Pharmaceutical Care Interventions in a Secondary-Care Hospital in Nigeria: A Cross-Sectional Survey
- 18 February 2026
- Published by Springer Nature in Cureus
- Vol. 18 (2)
Open AccessPatients’ Perspectives on Pharmaceutical Care Interventions in a Secondary-Care Hospital in Nigeria: A Cross-Sectional Survey
- Open Access
- 11 February 2026
- Published by MDPI AG in Preprints.org
Global Pharmaceutical Regulation: Comparative Frameworks and Operations
Pharmaceutical regulation and healthcare governmental agencies are central to protecting public health by governing clinical trials, market authorization, and post-market safety monitoring of medicinal products worldwide. Although substantial literature describes major established systems, particularly the United States Food and Drug Administration (FDA), Japan's Pharmaceuticals and Medical Devices Agency (PMDA), and the European Union regulatory network coordinated by the European Medicines Agency (EMA) together with national competent authorities, comparative analysis that integrate both established and emerging regulatory authorities remain limited. This review examines the core functions of regulatory affairs across the product life cycle and compares key features of global regulatory frameworks, including approval pathways, evidentiary expectations, data transparency, and pharmacovigilance approaches. It emphasizes the need for systems thinking to balance innovation with safety, efficacy, and quality, while anticipating unintended consequences of new therapies. This evaluation also highlights how region‑specific constraints and enabling infrastructures, such as national drug‑utilization registries in parts of Europe, can shape regulatory decision‑making and post‑market evaluation. Finally, this paper discusses opportunities for stronger international alliances and greater harmonization to improve efficiency, support timely patient access to essential therapies, strengthen risk management, and reinforce global health security in an increasingly interconnected healthcare environment.
- 11 February 2026
- Published by MDPI AG in Preprints.org
Open AccessGlobal Pharmaceutical Regulation: Comparative Frameworks and Operations
Pharmaceutical regulation and healthcare governmental agencies are central to protecting public health by governing clinical trials, market authorization, and post-market safety monitoring of medicinal products worldwide. Although substantial literature describes major established systems, particularly the United States Food and Drug Administration (FDA), Japan's Pharmaceuticals and Medical Devices Agency (PMDA), and the European Union regulatory network coordinated by the European Medicines Agency (EMA) together with national competent authorities, comparative analysis that integrate both established and emerging regulatory authorities remain limited. This review examines the core functions of regulatory affairs across the product life cycle and compares key features of global regulatory frameworks, including approval pathways, evidentiary expectations, data transparency, and pharmacovigilance approaches. It emphasizes the need for systems thinking to balance innovation with safety, efficacy, and quality, while anticipating unintended consequences of new therapies. This evaluation also highlights how region‑specific constraints and enabling infrastructures, such as national drug‑utilization registries in parts of Europe, can shape regulatory decision‑making and post‑market evaluation. Finally, this paper discusses opportunities for stronger international alliances and greater harmonization to improve efficiency, support timely patient access to essential therapies, strengthen risk management, and reinforce global health security in an increasingly interconnected healthcare environment.